Novel Monoclonal Antibodies Targeting Acinetobacter baumannii

Published date: June 6, 2016

Technology description

Market Opportunity

Multidrug-resistantA. baumanniiis a rapidly emerging pathogen in the healthcare setting, where it causes infections that include bacteremia, pneumonia, meningitis, urinary tract infection and wound infection. The organism's ability to survive under a wide range of environmental conditions and to persist on surfaces for extended periods make it a frequent cause of outbreaks of infection. The development of new therapies to target this pathogen would have a substantial impact on controlling its transmission and provide treatment where there are currently limited therapeutic agents available.

USC Solution

USC researchers have generated monoclonal antibodies that specifically targetA. baumannii. This has resulted in three new monoclonal antibodies. The intent is to develop a cocktail of monoclonal antibodies that bind to almost all strains as a therapeutic to treat deadlyA. baumanniiiinfections.

Value Proposition

Limited current therapeutics targetingA. baumannii
Monoclonal antibodies specifically targetA. baumannii
Novel composition of matter
Novel method for raising the monoclonal antibodies againstA. baumannii
Highly efficient binding capacity of antibody to its target

Application area

Monoclonal antibodies as a therapeutic to specifically targetA. baumannii

Institution

University of Southern California

联系我们

叶先生

电 话：021-65679356

手 机：13414935137

邮 箱：yeyingsheng@zf-ym.com